tenofovir has been researched along with levonorgestrel in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blakney, AK; Jiang, YH; Krogstad, EA; Woodrow, KA | 1 |
| Deese, J; Hubacher, D; Otunga, S; Steiner, MJ; Todd, CS; Van Damme, L; Wang, M | 1 |
| Asin, SN; Brache, V; Chandra, N; Clark, MR; Dezzutti, CS; Doncel, GF; Fichorova, R; Herold, BC; Hillier, SL; Kiser, P; Marzinke, MA; McCormick, T; Rollenhagen, C; Schwartz, JL; Stanczyk, FZ; Thurman, AR; Weiner, D | 1 |
| Anderson, SM; Doncel, GF; Gajer, P; Marzinke, MA; Ravel, J; Schwartz, JL; Thurman, AR; Yousefieh, N | 1 |
| Avenant, C; Dlamini, S; Enfield, K; Hapgood, JP; Kuipa, M | 1 |
| Allen, SA; Dabee, S; Doncel, GF; Feng, C; Gasper, M; Haugen, HS; Heffron, R; Jaspan, HB; McLellan-Lemal, E; Mudhune, V; Mugo, N; Njoroge, B; Nyagol, B; O'Connor, S; Ouma, E; Peacock, S; Ridzon, R; Thurman, AR; Wiener, J | 1 |
| Brache, V; Chandra, N; Clark, MR; Cochon, L; Doncel, GF; Erikson, DW; Fichorova, RN; Hanif, H; Herold, BC; Jacot, T; Ju, S; Marzinke, MA; Ouattara, LA; Parikh, U; Peet, M; Schwartz, JL; Thurman, AR; Tolley, E; Yousefieh, N | 1 |
| Cohen, CE; Garvey, L; Heskin, J; Leung, S; Naous, N; Oddie, PD | 1 |
| Chinula, L; Corbett, AH; Cottrell, ML; Gajer, P; Haddad, LB; Hurst, S; Kourtis, AP; Lantz, AM; Nelson, JAE; Nicol, MR; Ravel, J; Tang, JH; Tegha, G | 1 |
2 review(s) available for tenofovir and levonorgestrel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug-induced liver injury secondary to increased levonorgestrel exposure in a patient taking ritonavir.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Darunavir; Female; HIV Infections; Humans; Levonorgestrel; Ritonavir; Tenofovir | 2023 |
5 trial(s) available for tenofovir and levonorgestrel
| Article | Year |
|---|---|
Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Contraceptive Agents, Female; Deoxycytidine; Drug Combinations; Drug Implants; Emtricitabine; Female; HIV Infections; Humans; Kenya; Levonorgestrel; Longitudinal Studies; Organophosphonates; Polypharmacy; Prospective Studies; Tenofovir; Young Adult | 2015 |
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
Topics: Adult; Contraceptive Devices, Female; Female; HIV Infections; HIV-1; Humans; Levonorgestrel; Models, Biological; Tenofovir | 2018 |
Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Contraceptive Agents, Hormonal; Contraceptive Devices, Female; Device Removal; Female; Herpes Genitalis; HIV Infections; Humans; Levonorgestrel; Microbiota; Middle Aged; Mucous Membrane; Organophosphates; Tenofovir; Vagina; Young Adult | 2019 |
Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya.
Topics: Administration, Intravaginal; Female; HIV Infections; Humans; Kenya; Levonorgestrel; Microbiota; RNA, Ribosomal, 16S; Tenofovir; Vagina | 2022 |
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
Topics: Anovulation; Antiviral Agents; Contraceptive Agents; Contraceptive Devices, Female; Diphosphates; Female; HIV Core Protein p24; HIV Infections; Humans; Levonorgestrel; Male; Semen; Tenofovir | 2022 |
4 other study(ies) available for tenofovir and levonorgestrel
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Contraceptive Agents, Female; Diffusion; Drug Combinations; Drug Design; Electroplating; HeLa Cells; HIV-1; Humans; Levonorgestrel; Nanocomposites; Nanofibers; Organophosphonates; Rotation; Tenofovir | 2014 |
Maraviroc, tenofovir disoproxil fumarate and dapivirine, activate progesterone receptor B in the absence of progestogens.
Topics: Anti-HIV Agents; Binding, Competitive; Cell Line; Contraceptive Agents, Hormonal; HIV Infections; HIV-1; Humans; Immunologic Factors; In Vitro Techniques; Levonorgestrel; Maraviroc; Phosphorylation; Progesterone Congeners; Pyrimidines; Receptors, Progesterone; Tenofovir; Transcriptional Activation | 2020 |
Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Hormonal Contraception; Humans; Lamivudine; Levonorgestrel; Malawi; Medroxyprogesterone Acetate; Microbiota; Tenofovir; Vagina | 2023 |